Myasthenia Gravis Support Group
Myasthenia gravis (MG) is a neuromuscular disease leading to fluctuating muscle weakness and fatiguability. The hallmark of myasthenia gravis is muscle weakness that increases during periods of activity and improves after periods of rest. Although myasthenia gravis may affect any voluntary muscle, muscles that control eye and eyelid movement, facial expression, and...
https://www.chihealth.com/en/about-us/press-room/news-center/2020-news/covid-outpatient-therapeutic.html
The article seems to say that we should take it.
Hope you get through Covid smoothly,
Good Luck
Russ
I also found this.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272991/
Talked to my Neuro's Nurse. They do not know much about this therapy and Bows to my PCP's position. Clearly this is new stuff, but had hoped that he, my Neuro, is familiar with this Therapy. To be fair my PCP was also not fluent in this therapy either but had heard about it. She, my PCP, did some research and thinks it will not cause any damage.
Still have a minor headache and sore throat. No temp.
We shall see. :-)
Good Luck
Russ
No test results yet.
Feeling OK. :-)
https://www.bloomberg.com/news/articles/2021-01-07/trump-prepares-pardon-list-for-aides-and-kin-and-maybe-himself?sref=NtzHDUJv&fbclid=IwAR2WluQ8zr8MGiTbnrX_9PB5McfNaaN_vfFGMQVTu4P4q8FKbq1a-sVNwVQ
RESULTS
A total of 160 patients underwent randomization. In the intention-to-treat population, severe respiratory disease developed in 13 of 80 patients (16%) who received convalescent plasma and 25 of 80 patients (31%) who received placebo (relative risk, 0.52; 95% confidence interval [CI], 0.29 to 0.94; P=0.03), with a relative risk reduction of 48%. A modified intention-to-treat analysis that excluded 6 patients who had a primary end-point event before infusion of convalescent plasma or placebo showed a larger effect size (relative risk, 0.40; 95% CI, 0.20 to 0.81). No solicited adverse events were observed.
CONCLUSIONS
Early administration of high-titer convalescent plasma against SARS-CoV-2 to mildly ill infected older adults reduced the progression of Covid-19. (Funded by the Bill and Melinda Gates Foundation and the Fundación INFANT Pandemic Fund; Dirección de Sangre y Medicina Transfusional del Ministerio de Salud number, PAEPCC19, Plataforma de Registro Informatizado de Investigaciones en Salud number, 1421, and ClinicalTrials.gov number, NCT04479163. opens in new tab.)
No test results yet. I must be OK.
Needless to say, testing here in Texas, is poor and these days the labs are very busy.
Turns out my test was sent to California because the Texas Labs are overwhelmed.
Thanks to everyone for your responses.
Scott
- Nan
Russ